Biopharma Quarterly Dealmaking Statistics, Q4 2018
A look at financing, M&A and alliance activity October-December 2018
At $10.9bn, biopharma financing was at its lowest quarter of the year. GSK’s $5.1bn acquisition of oncology player Tesaro led M&As. And 13 partnerships exceeded the $1bn mark, led by two agreements focused on RNAi.